Knight Therapeutics

Aging Global Populations And Latin America Will Expand Pharma Access

AnalystHighTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

29 Aug 25

AnalystHighTarget's Fair Value

CA$9.93

35.2% undervalued

05 Sep

CA$6.44

14.2%

-0.9%

14.2%

-0.9%

Edit anytime before Aug 29 9:30 PM. Then post Updates to your followers.

Author's Valuation

CA$9.9

35.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CA$9.9

35.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

8.37%

Pharma revenue growth rate

0.59%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.97%

Calculation

CA$25.46m

Earnings '28

44.56x

PE Ratio '28

CA$1.13b

Market Cap '28

CA$1.13b

Market Cap '28

96.28m

No. shares '28

CA$11.78

Share Price '28

CA$11.78 Share Price '28

Discounted to 2025 @ 5.97% p.a.

CA$9.90

Fair Value '25